Seminars in arthritis and rheumatism · 2026
A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soowamber Medha L, Bond Milena, Sanchez-Alvarez Catalina, Langford Carol A, Aydin Sibel Zehra, Buttgereit Frank, Camellino Dario, Cid Maria C, Grayson Peter C, Hellmich Bernhard, Hendry Alison, Kermani Tanaz A, Khalidi Nader A, Mackie Sarah L, Mahr Alfred, Matteson Eric L, Maz Mehrdad, Merkel Peter A, Monach Paul A, Neill Lorna, Ponte Cristina, Salvarani Carlo, Schmidt Wolfgang A, Villiger Peter M, Warrington Kenneth J, Dejaco Christian, Ramiro Sofia, Touma Zahi
Аннотация
OBJECTIVE: To identify the most important and relevant items to consider when developing criteria to measure response to treatment in giant cell arteritis (GCA).
METHODS: As part of an ongoing project to develop response criteria for GCA, a 4-round web-based Delphi exercise was conducted. Participants included patients with GCA and health professionals with expertise in GCA. Participants rated the importance (1=lowest, 9=highest) of 51 items selected based on a systematic literature review, grouped into six domains, and could suggest additional items. Items scored 7-9 by at least 70% of health professionals and 70% of patients were considered critically important and to have reached consensus. In the last round of the Delphi, participants ranked the top 10 most relevant items. A task force (n = 32 members) meeting followed to review the Delphi results, discuss rankings, and finalize the selection of items.
RESULTS: One hundred eighty-seven physicians and 85 patients, from 38 countries, participated in the Delphi exercise. Twenty-four (75%) task force members participated in the virtual meeting. Thirteen new items were proposed in round 1. Twenty-four items were rated as critically important. No items were excluded during any round, and consensus was not reached for 40 items. The top 3 highest rated items by both patients and physicians were headache (ranked highest by 52%), amaurosis fugax (highest=10%), and jaw claudication (highest=7%). Twelve items were selected for the next phase of the project.
CONCLUSION: Experts and patients identified 12 items considered important for measuring response to treatment in GCA.
METHODS: As part of an ongoing project to develop response criteria for GCA, a 4-round web-based Delphi exercise was conducted. Participants included patients with GCA and health professionals with expertise in GCA. Participants rated the importance (1=lowest, 9=highest) of 51 items selected based on a systematic literature review, grouped into six domains, and could suggest additional items. Items scored 7-9 by at least 70% of health professionals and 70% of patients were considered critically important and to have reached consensus. In the last round of the Delphi, participants ranked the top 10 most relevant items. A task force (n = 32 members) meeting followed to review the Delphi results, discuss rankings, and finalize the selection of items.
RESULTS: One hundred eighty-seven physicians and 85 patients, from 38 countries, participated in the Delphi exercise. Twenty-four (75%) task force members participated in the virtual meeting. Thirteen new items were proposed in round 1. Twenty-four items were rated as critically important. No items were excluded during any round, and consensus was not reached for 40 items. The top 3 highest rated items by both patients and physicians were headache (ranked highest by 52%), amaurosis fugax (highest=10%), and jaw claudication (highest=7%). Twelve items were selected for the next phase of the project.
CONCLUSION: Experts and patients identified 12 items considered important for measuring response to treatment in GCA.